Antagonism between the Anti-Inflammatory Activity of the Cannabinoid WIN 55212-2 and SR 141716A
Citations Over Time
Abstract
The CB1/CB2 receptor agonist WIN 55212-2 (0.75 mg/kg, i.v.) caused a significant reduction in neurogenic plasma extravasation induced by electrical stimulation of the saphenous nerve in anesthetized rats; WIN 55212-2 at 2.5-10 mg/kg, s.c., also produced a significant reduction in the carrageenan-induced paw edema in conscious rats. The selective CB1 antagonist SR 141716A (0.075-0.75 mg/kg i.v.) antagonized the WIN 55212-2 effects in the plasma extravasation model and antagonized the WIN 55212-2 (2.5 mg/kg, s.c.)-induced decreases in rectal temperature and increases in tail-flick latencies. However, SR 141716A (10 mg/kg, p.o.) failed to antagonize the effects of Win 55212-2 (2.5 mg/kg, s.c.) in the carrageenan model, suggesting that cannabinoid receptors found in the periphery may be able to modulate inflammatory processes in rats.
Related Papers
- → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
- → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
- → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
- → Pharmacological characterization of the cannabinoid CB1 receptor PET ligand ortholog, [3H]MePPEP(2010)6 cited
- → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited